TrialsgrambetaRCTs are beautiful

2022 ESC Guidelines on cardio-oncology

This guideline cites 3 of the 199 landmark trials in our Cardiology register.

Issued by
ESC
Year
2022
Source
Lyon AR, López-Fernández T, et al. Eur Heart J. 2022;43(41):4229–4361.doi 10.1093/eurheartj/ehac244

The first ESC cardio-oncology guideline builds a full pathway: baseline cardiovascular risk stratification before cancer therapy, surveillance during it, and management of cancer-therapy-related cardiac dysfunction afterwards. The randomised cardioprotection evidence is small and rests on imaging surrogates rather than hard outcomes — a limitation the guideline states openly. The register's trials are grouped by protective strategy below.

Neurohormonal cardioprotection3

  • 2017MANTICORE 101-Breast⁠Cardiology · Cardioprotection · HER2 cardiotoxicityIn 94 patients with HER2-positive early breast cancer starting adjuvant trastuzumab, perindopril or bisoprolol did not prevent trastuzumab-mediated left ventricular remodelling, although both attenuated the fall in ejection fraction, compared with placebo.Read →
  • 2016PRADA⁠Cardiology · Cardioprotection · Anthracycline cardiotoxicityIn 130 women with early breast cancer receiving adjuvant anthracycline-based chemotherapy, concomitant candesartan attenuated the early decline in left ventricular ejection fraction on cardiac MRI, whereas metoprolol did not, compared with placebo.Read →
  • 2013OVERCOME⁠Cardiology · Cardioprotection · Neurohormonal prophylaxisIn 90 patients with malignant haemopathies undergoing intensive chemotherapy or autologous stem-cell transplantation, enalapril plus carvedilol started before chemotherapy preserved left ventricular ejection fraction and reduced death or heart failure at 6 months compared with no cardioprotective treatment.Read →

Published since the guideline2

  • 2025SAFE 2025⁠Cardiology · Cardioprotection · Anthracycline cardiotoxicityIn 262 women with non-metastatic breast cancer receiving anthracycline-based chemotherapy, ramipril, bisoprolol or both for 12 months reduced subclinical cardiac damage at 24 months compared with placebo.Read →
  • 2023STOP-CA⁠Cardiology · Cardioprotection · Statin cardioprotectionIn 300 patients with lymphoma scheduled for anthracycline-based chemotherapy, atorvastatin 40 mg daily for 12 months reduced the proportion of patients with an ejection-fraction decline of at least 10 % to below 55 % compared with placebo.OR 2.995% CI 1.4-6.4Read →

Cited landmark trials not yet in the register4

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2018CECCY

    Carvedilol did not prevent the anthracycline-related fall in ejection fraction.

  • 2018ICOS-ONE

    Enalapril given pre-emptively versus troponin-triggered — no difference.

  • 2019SAFE-HEaRT

    Continuing HER2-targeted therapy in patients with mildly reduced ejection fraction.

  • 2022PROACT

    Enalapril during high-dose anthracycline therapy, with troponin release as the endpoint.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.